- Report
- June 2024
- 140 Pages
Latin America
From €3459EUR$3,869USD£2,986GBP
- Report
- June 2023
- 140 Pages
Global
From €4425EUR$4,949USD£3,820GBP
- Report
- May 2023
- 140 Pages
Global
From €4425EUR$4,949USD£3,820GBP
- Report
- April 2024
- 140 Pages
Global
From €4425EUR$4,949USD£3,820GBP
- Report
- May 2023
- 147 Pages
Global
From €4425EUR$4,949USD£3,820GBP
- Report
- July 2024
- 108 Pages
North America
From €3085EUR$3,450USD£2,663GBP
- Report
- July 2024
- 112 Pages
Europe
From €3085EUR$3,450USD£2,663GBP
- Report
- November 2023
- 176 Pages
Global
From €3979EUR$4,450USD£3,435GBP
- Report
- September 2023
- 119 Pages
From €3085EUR$3,450USD£2,663GBP
- Report
- September 2023
- 143 Pages
Europe
From €3085EUR$3,450USD£2,663GBP
- Report
- April 2025
- 163 Pages
Europe
From €3085EUR$3,450USD£2,663GBP
- Report
- April 2025
- 161 Pages
Asia Pacific
From €3085EUR$3,450USD£2,663GBP
- Report
- April 2025
- 142 Pages
North America
From €3085EUR$3,450USD£2,663GBP
- Report
- April 2025
- 150 Pages
Middle East, Africa
From €3085EUR$3,450USD£2,663GBP
- Report
- April 2025
- 137 Pages
From €3085EUR$3,450USD£2,663GBP
- Report
- April 2024
- 101 Pages
Europe
From €3085EUR$3,450USD£2,663GBP
- Report
- January 2024
- 119 Pages
Europe
From €3085EUR$3,450USD£2,663GBP
- Report
- January 2024
- 112 Pages
Asia Pacific
From €3085EUR$3,450USD£2,663GBP
- Report
- January 2024
- 110 Pages
North America
From €3085EUR$3,450USD£2,663GBP
- Report
- January 2024
- 92 Pages
From €3085EUR$3,450USD£2,663GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more